



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books	
Search	PubMed	<input type="checkbox"/> for						Go	Clear
		Limits	Preview/Index	History	Clipboard	Details			

Display	Abstract	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	<input type="checkbox"/>
---------	----------	--------------------------	----------	--------------------------	------	--------------------------	---------	------	--------------------------

☐ 1: Am J Respir Crit Care Med 2000 Apr;161(4 Pt 1):1136-42

Links

Entrez
PubMed

FREE full text article at
www.ajrccm.org

Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.

Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr.

PubMed
Services

Sepulveda Ambulatory Care and Nursing Home, Veterans Administration Greater Los Angeles Healthcare System, Sepulveda, CA, USA.

Related
Resources

Tiotropium (Spiriva; Ba679BR) is a new-generation, long-acting anticholinergic bronchodilator that has muscarinic M(1) and M(3) receptor subtype selectivity. A multicenter, randomized, double-blind, parallel group, placebo-controlled study was conducted to evaluate the dose-response characteristics of tiotropium inhalation powder given once daily to stable patients with chronic obstructive pulmonary disease (COPD). Patients (mean FEV(1) = 1.08 L [42% predicted]) were randomized to receive 0, 4.5, 9, 18, or 36 microg tiotropium once daily at noon for 4 wk, with spirometry done before and hourly for 6 h after dosing. Patients measured and recorded their peak expiratory flow rates (PEFRs) three times each day. Significant dose-related improvement in FEV(1) and significant improvement in FVC occurred within 1 h after the first dose of tiotropium as compared with placebo. Over the 29 d of the study, all doses of tiotropium produced significant increases over placebo in trough (i.e., as measured spirometrically at 20 to 24 h after the previous dose and just before the next dose of tiotropium), peak, and 6-h postdose average FEV(1) and FVC, and in PEFR, without a significant difference among the different doses investigated. PEFR gradually returned to pretreatment baseline levels over a 3-wk evaluation period following the discontinuation of tiotropium. The overall safety profile for the tiotropium doses was similar to that for placebo. In summary, tiotropium was shown to be safe and effective in doses ranging from 4.5 to 36 microg delivered once daily. The improvements in spirometry with once-daily dosing confirm the long duration of action of tiotropium reported in single-dose studies, and its sustained improvement of spirometric measures over the 1 mo of testing in the study points to utility of tiotropium as a maintenance bronchodilator for patients with COPD. On the basis of the comparable bronchodilator response at doses from 9 to 36 microg, and advantages suggested by the safety profile at doses below 36 microg in this study, a dose of 18 microg once daily was selected for use in long-term studies of the safety and efficacy of tiotropium.

Publication Types:

- Clinical Trial
- Multicenter Study
- Randomized Controlled Trial

PMID: 10764302 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Show:	20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	-------	----	---	------	---	---------	------	---

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed	for pramipexol and pulmonary						Go	Clear
Limits		Preview/Index		History		Clipboard		Details

Display	Summary	Show: 20	Sort	Send to	Text
Items 1-3 of 3					One page.

Entrez
PubMed

☐ 1: Lehr E. [Related Articles, Links](#)

Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice.
Psychopharmacology (Berl). 2002 Oct;163(3-4):495-500.
PMID: 12373450 [PubMed - indexed for MEDLINE]

PubMed
Services

☐ 2: Oechsner M, Groenke L, Mueller D. [Related Articles, Links](#)

Pleural fibrosis associated with dihydroergocryptine treatment.
Acta Neurol Scand. 2000 Apr;101(4):283-5.
PMID: 10770528 [PubMed - indexed for MEDLINE]

☐ 3: Gottwald MD, Bainbridge JL, Dowling GA, Aminoff MJ, Alldredge BK. [Related Articles, Links](#)

New pharmacotherapy for Parkinson's disease.
Ann Pharmacother. 1997 Oct;31(10):1205-17. Review.
PMID: 9337447 [PubMed - indexed for MEDLINE]

Related
Resources

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

THOMSON
MICROMEDEX

PDR® Electronic Library™

PDR SUITE | **INTERACTIONS** | **STEDMAN'S DICTIONARY**

KEYWORD SEARCH | **BROWSE** | **FULL TEXT SEARCH** | **UPDATES**

[Return to
Thomson Subscription Page](#)[Log Out](#)[Keyword Search](#) > **Matching Brands and GENERICS****Your Search:**

• tiotropium

No results found for this search.

1. Make sure you are looking for the keyword within the correct list.
2. If you are unsure of the spelling, try typing in only the first few letters.

[Home](#) || [Warranty and Disclaimer](#) || [About Us](#) || [Help](#) || [Log Out](#)
[Contact Us](#) or call the 24-Hour Tech Support line at 1-800-525-9083, option '3'
Copyright© 2002-2003 Thomson MICROMEDEX. All rights reserved.

THOMSON
MICROMEDEX




PDR® Electronic Library™

PDR SUITE | INTERACTIONS | STEDMAN'S DICTIONARY


KEYWORD SEARCH | BROWSE | FULL TEXT SEARCH | UPDATES

Return to
Thomson Subscription Page

Log Out

[Keyword Search](#) > **Search Results**

Your Search: 

• PRAMIPEXOLE
DIHYDROCHLORIDE

Showing Results 1 through 1 of 1

Mirapex Tablets (Pharmacia & Upjohn)
Pramipexole Dihydrochloride

[Home](#) || [Warranty and Disclaimer](#) || [About Us](#) || [Help](#) || [Log Out](#)
[Contact Us](#) or call the 24-Hour [Tech Support](#) line at 1-800-525-9083, option '3'
Copyright© 2002-2003 Thomson MICROMEDEX. All rights reserved.



SCIENCE @ DIRECT

Register or Login: Password: [Go](#) [Athens Login](#)

[Home](#) [Journals](#) [Abstract Databases](#) [Reference Works](#) [My Alerts](#) [My Profile](#)

[Help](#)

WELCOME GUEST USER [info](#)

International Journal of Pharmaceutics

Volume 191, Issue 2, 30 November 1999, Pages 131-140

doi:10.1016/S0378-5173(99)00296-3 [? Cite or link using doi](#)

Copyright © 1999 Elsevier Science B.V. All rights reserved.

This Document

- ▶ **Abstract**
- [Full Text + Links](#)
- [PDF \(140 K\)](#)

Actions

- [E-mail Article](#)

Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans

Yuqun Zheng[✉], Kennan C. Marsh, Richard J. Bertz, Tawakol El-Shourbagy and Akwete L. Adjei

Pharmaceutical Products Division, Formulation Development Center, Abbott Laboratories, 1401 Sheridan Road, North Chicago, IL 60064-6246, USA

Received 30 March 1999; revised 13 August 1999; accepted 16 August 1999. Available online 15 November 1999.

Abstract

The purpose of this study was to evaluate the feasibility of intrapulmonary delivery of ABT-431, a selective D1 receptor agonist. Following intratracheal instillation of the drug solution, the lung bioavailability was found to be approximately 75% in dogs. An aerosol suspension formulation was then developed by dispersing the drug in tetrafluoroethane, HFC-134a, with the aid of poloxamer 124 and vitamin E. This ABT-431 MDI aerosol formulation showed about 40% of the particles emitted from the valve and actuator system to be under 5 μm in diameter. Also, the primary package (15 mL aluminum container, DF10/ACT-150 valve, and Micron-4-actuator with the orifice 0.4 mm) was satisfactory for accurate and reproducible dosimetry. Using tracheostomized beagle dogs, the C_{max} following tracheal administration of 5 mg aerosolized ABT-431 was found to be $13.3 \pm 0.9 \text{ ng ml}^{-1}$ and the AUC_{0-24} was estimated at $33.2 \pm 10.6 \text{ h ng ml}^{-1}$. The lung bioavailability of the aerosolized drug was 34% compared to intravenous injection in dogs. In humans, results from a single rising dose study demonstrated that rapid absorption of ABT-431 following oral inhalation administration resulted in a dose-dependent increase in the area under the plasma-time curve at dosage levels between 3.3 and 13.2 mg. There is a possibility of up to 25% absorption of the drug from human lung. Thus, pulmonary bioavailability of ABT-431 is significantly greater than that of oral administration. Also, these findings suggest that small and lipophilic

compounds, especially with hepatic first pass effect, may be effectively delivered systemically using oral inhalation aerosols.

Author Keywords: Dopamine D-1; Agonist; ABT-431; Metered-dose inhalation; Pulmonary absorption; Pulmonary bioavailability

✉ Corresponding author. Tel.: +1-847-937-0783; fax: +1-847-937-5611; email: jack.zheng@abbott.com

International Journal of Pharmaceutics

Volume 191, Issue 2 , 30 November 1999 , Pages 131-140

This Document

► **Abstract**

- [Full Text + Links](#)
- [PDF \(140 K\)](#)

Actions

- [E-mail Article](#)

[Home](#)

[Journals](#)

[Abstract Databases](#)

[Reference Works](#)

[My Alerts](#)

[My Profile](#)

[? Help](#)

Send [feedback](#) to ScienceDirect

Software and compilation © 2003 ScienceDirect. All rights reserved.

ScienceDirect® is an Elsevier Science B.V. registered trademark.

Your use of this service is governed by [Terms and Conditions](#). Please review our [Privacy Policy](#) for details on how we protect information that you supply.